Wordt geladen...
Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects
INTRODUCTION: Latanoprostene bunod is a novel nitric oxide (NO)-donating prostaglandin F2α receptor agonist in clinical development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. We evaluated the effect of latanoprostene bunod 0.024% inst...
Bewaard in:
| Gepubliceerd in: | Adv Ther |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer Healthcare
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4662725/ https://ncbi.nlm.nih.gov/pubmed/26563323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-015-0260-y |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|